| BAT1308 / Bio-Thera Solutions |
NCT06123884: BAT1308 Combined With Platinum-Based Chemotherapy± Bevacizumab For PDL1-Positive (CPS ≥1) Cervical Cancer |
|
|
| Not yet recruiting | 2/3 | 526 | RoW | Recombinant humanized anti-PD-1 monoclonal antibody injection, BAT1308 injection, Cisplatin, Shunbo, Bevacizumab Injection, Pobevcy, carboplatin, Bobei, Paclitaxel for Injection, Tesu | Bio-Thera Solutions | Cervical Cancer | 04/24 | 08/24 | | |
NCT06321068: BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer |
|
|
| Active, not recruiting | 2/3 | 140 | RoW | carboplatin, Bobei, Paclitaxel, Tesu, Recombinant humanized anti-PD-1 monoclonal antibody injection, BAT1308 injection | Bio-Thera Solutions | Endometrial Cancer | 11/24 | 12/24 | | |
NCT06341114: A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 112 | RoW | BAT8008 injection, BAT1308 injection | Bio-Thera Solutions | Advanced Solid Tumors | 04/26 | 07/26 | | |
NCT05109650: Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumour Patients |
|
|
| Terminated | 1 | 13 | RoW | BAT6026, Recombinant Anti-OX40 Antibody Solution for Injection, BAT1308, Recombinant Anti-PD-1 Antibody Solution for Injection | Bio-Thera Solutions | Advanced Solid Tumour | 03/23 | 03/23 | | |
NCT05073484: Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients |
|
|
| Terminated | 1 | 13 | RoW | BAT6021, Recombinant Humanized Anti-TIGIT Antibody Solution for Injection, BAT1308, Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection | Bio-Thera Solutions | Advanced Solid Tumor | 03/23 | 03/23 | | |
ChiCTR2000033713: A Phase I Clinical Trial of BAT1308 Injection on the Safety, Tolerability and Pharmacokinetics in Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 18 | | BAT1308 Injection 100mg ;BAT1308 Injection 300mg ;BAT1308 Injection 600mg | He'nan Cancer Hospital; Bio-Thera Solutions, Ltd., Self-finance | Solid Tumors | | | | |
NCT05155722: Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT1308 in Advanced Solid Tumors |
|
|
| Recruiting | 1 | 148 | RoW | BAT1308 | Bio-Thera Solutions | Advanced Solid Tumor | 12/23 | 12/23 | | |
NCT06139536: Assessment of Safety, Tolerability and Pharmacokinetics With BAT4706 and BAT1308 in Advanced Solid Tumors Patients |
|
|
| Recruiting | 1 | 210 | RoW | BAT4706 Injection, Fc-glycosylated recombinant fully humanized anti-CTLA-4 monoclonal antibody injection, BAT1308 Injection, Recombinant humanized anti PD-1 monoclonal antibody injection | Bio-Thera Solutions | Advanced Solid Tumor | 12/25 | 02/26 | | |
